Brief: Merus’Presents Interim Data On Petosemtamab In Metastatic Colorectal Cancer
24/10/2025 17:29
Oct 24 (Reuters) - Merus NV 2GH.F: MERUS’ INTERIM DATA ON PETOSEMTAMAB IN METASTATIC COLORECTAL CANCER DEMONSTRATES MONOTHERAPY ACTIVITY AND ROBUST RESPONSE RATE IN COMBINATION WITH FOLFOX/FOLFIRI WITH WELL TOLERATED SAFETY Source text: ID:nGNX3Qf1pL Further company coverage: 2GH.F ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab